Retevmo was evaluated in the single-arm, multi-center Phase 1/2 LIBRETTO-001 trial, the largest trial (N=702) of patients with RET -driven cancers. The trial enrolled both treatment-naive patients and ...

INDIANAPOLIS, Aug. 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the ...

Median progression free survival in the selpercatinib group was not reached and was 16.8 months in the cabozantinib/vandetanib group. The Food and Drug Administration ...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo. The US regulator says Retevmo (selpercatinib, ...

A preliminary report depicted confusion in the cockpit shortly before an Air India jetliner crashed, killing 260 people last month, after the plane's engine fuel cutoff switches almost simultaneously ...

Retevmo is an U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.

Retevmo as a treatment for patients with advanced RET-mutant medullary thyroid cancer “is very exciting,” as treatment options were previously limited, an expert told CURE®. Treatment with Retevmo ...

The approvals were based on data from the LIBRETTO-001 trial. The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo ® (selpercatinib) for adults with locally advanced or ...

Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer. Retevmo (selpercatinib) versus ...

- Approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer - Accelerated approval based on data from ...

About Retevmo® (selpercatinib, 40 mg & 80 mg capsules) Retevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with CNS ...

INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), ...